Ossiform

Ossiform develops bioactive bone substitutes that provide structure and consistency while facilitating the natural forming of new bone. The company 3D prints bone substitutes from beta-tricalcium phosphate with indication-specific biomechanical considerations to support bone healing and simplify complex procedures. Ossiform's technology enables surgeons to reconstruct bone without the risks of permanent foreign body implantation or the inherent variability of allografts. The bio-integrative material remodels into new vascularized bone with balanced resorption rates, offering controlled cortical and cancellous components. ISO 13485 certified, Ossiform also offers a research line of bioceramic bone-mimicking scaffolds for cell and bacteria studies, tissue engineering, disease modeling, and drug screening as an animal-free alternative. Founded in 2017, headquartered in Odense, Denmark, The company has raised $20.6M at the Series B stage, backed by investors including Asimov Ventures, West Hill Capital, Nordic Startup Awards, Innovationsfonden, moabiotech.com..